AU2007275365A1 - RNA interference mediated inhibition of Proprotein Convertase Subtilisin Kexin 9 (PCSK9) gene expression using short interfering nucleic acid (siNA) - Google Patents

RNA interference mediated inhibition of Proprotein Convertase Subtilisin Kexin 9 (PCSK9) gene expression using short interfering nucleic acid (siNA) Download PDF

Info

Publication number: AU2007275365A1
Authority: AU; Australia
Prior art keywords: nucleotides; nucleic acid; strand; sina; double stranded
Prior art date: 2006-07-17
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

AU2007275365A

Other languages

English (en)

Inventor

Roberto Guerciolini

Vasant Jadhav

James Mcswiggen

Narendra K. Vaish

Chandra Vargeese

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Sirna Therapeutics Inc

Original Assignee

Sirna Therapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-07-17

Filing date

2007-07-17

Publication date

2008-01-24

2006-07-17 Priority claimed from US11/487,788 external-priority patent/US20070173473A1/en

2007-07-17 Application filed by Sirna Therapeutics Inc filed Critical Sirna Therapeutics Inc

2008-01-24 Publication of AU2007275365A1 publication Critical patent/AU2007275365A1/en

Status Abandoned legal-status Critical Current

Links

150000007523 nucleic acids Chemical class 0.000 title claims description 358
102000039446 nucleic acids Human genes 0.000 title claims description 327
108020004707 nucleic acids Proteins 0.000 title claims description 327
101710172072 Kexin Proteins 0.000 title claims description 14
230000009368 gene silencing by RNA Effects 0.000 title description 173
238000012228 RNA interference-mediated gene silencing Methods 0.000 title description 172
230000014509 gene expression Effects 0.000 title description 133
230000002452 interceptive effect Effects 0.000 title description 71
230000001404 mediated effect Effects 0.000 title description 20
230000005764 inhibitory process Effects 0.000 title description 15
125000003729 nucleotide group Chemical group 0.000 claims description 675
239000002773 nucleotide Substances 0.000 claims description 655
230000000692 anti-sense effect Effects 0.000 claims description 330
108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 194
230000000295 complement effect Effects 0.000 claims description 167
239000002213 purine nucleotide Substances 0.000 claims description 161
108091081021 Sense strand Proteins 0.000 claims description 159
150000003212 purines Chemical class 0.000 claims description 142
239000002719 pyrimidine nucleotide Substances 0.000 claims description 115
150000003230 pyrimidines Chemical class 0.000 claims description 102
239000000203 mixture Substances 0.000 claims description 74
108091028664 Ribonucleotide Proteins 0.000 claims description 65
239000002336 ribonucleotide Substances 0.000 claims description 65
125000002652 ribonucleotide group Chemical group 0.000 claims description 52
239000005547 deoxyribonucleotide Substances 0.000 claims description 51
RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims description 42
108091028043 Nucleic acid sequence Proteins 0.000 claims description 37
108091034117 Oligonucleotide Proteins 0.000 claims description 37
150000002632 lipids Chemical class 0.000 claims description 33
125000002637 deoxyribonucleotide group Chemical group 0.000 claims description 32
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims description 26
230000037361 pathway Effects 0.000 claims description 17
239000003085 diluting agent Substances 0.000 claims description 16
239000003937 drug carrier Substances 0.000 claims description 16
235000009776 Rathbunia alamosensis Nutrition 0.000 claims description 11
125000001153 fluoro group Chemical group F* 0.000 claims description 10
239000002105 nanoparticle Substances 0.000 claims description 6
244000089409 Erythrina poeppigiana Species 0.000 claims 5
102000040430 polynucleotide Human genes 0.000 description 226
108091033319 polynucleotide Proteins 0.000 description 226
239000002157 polynucleotide Substances 0.000 description 226
108090000623 proteins and genes Proteins 0.000 description 216
210000004027 cell Anatomy 0.000 description 137
239000002585 base Substances 0.000 description 104
239000004055 small Interfering RNA Substances 0.000 description 95
108020004459 Small interfering RNA Proteins 0.000 description 84
238000000034 method Methods 0.000 description 79
230000004048 modification Effects 0.000 description 73
238000012986 modification Methods 0.000 description 73
238000007385 chemical modification Methods 0.000 description 62
239000003446 ligand Substances 0.000 description 59
210000001519 tissue Anatomy 0.000 description 59
230000000694 effects Effects 0.000 description 55
102000040650 (ribonucleotides)n+m Human genes 0.000 description 53
-1 (e.g. Substances 0.000 description 45
239000012634 fragment Substances 0.000 description 45
108090000765 processed proteins & peptides Proteins 0.000 description 40
102000004169 proteins and genes Human genes 0.000 description 38
238000003776 cleavage reaction Methods 0.000 description 37
230000007017 scission Effects 0.000 description 37
239000003112 inhibitor Substances 0.000 description 36
239000000562 conjugate Substances 0.000 description 35
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 32
235000018102 proteins Nutrition 0.000 description 30
108020004414 DNA Proteins 0.000 description 28
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 28
230000001939 inductive effect Effects 0.000 description 28
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 27
229920006317 cationic polymer Polymers 0.000 description 26
235000000346 sugar Nutrition 0.000 description 26
239000003795 chemical substances by application Substances 0.000 description 25
201000010099 disease Diseases 0.000 description 25
239000013598 vector Substances 0.000 description 22
125000000217 alkyl group Chemical group 0.000 description 21
239000002679 microRNA Substances 0.000 description 21
229920001223 polyethylene glycol Polymers 0.000 description 21
229920000642 polymer Polymers 0.000 description 21
230000002194 synthesizing effect Effects 0.000 description 21
230000008685 targeting Effects 0.000 description 21
239000002202 Polyethylene glycol Substances 0.000 description 20
108091027967 Small hairpin RNA Proteins 0.000 description 20
KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 19
108010016790 RNA-Induced Silencing Complex Proteins 0.000 description 19
102000000574 RNA-Induced Silencing Complex Human genes 0.000 description 19
102000004196 processed proteins & peptides Human genes 0.000 description 19
101150094724 PCSK9 gene Proteins 0.000 description 18
230000000670 limiting effect Effects 0.000 description 18
229920002873 Polyethylenimine Polymers 0.000 description 17
230000001413 cellular effect Effects 0.000 description 17
150000001875 compounds Chemical class 0.000 description 17
239000002777 nucleoside Substances 0.000 description 17
235000012000 cholesterol Nutrition 0.000 description 16
238000000338 in vitro Methods 0.000 description 16
108020004999 messenger RNA Proteins 0.000 description 16
150000003833 nucleoside derivatives Chemical class 0.000 description 16
208000035657 Abasia Diseases 0.000 description 15
108700011259 MicroRNAs Proteins 0.000 description 15
239000000178 monomer Substances 0.000 description 15
102100030209 Elongin-B Human genes 0.000 description 14
101001011859 Homo sapiens Elongin-A Proteins 0.000 description 14
101001011846 Homo sapiens Elongin-B Proteins 0.000 description 14
101000881731 Homo sapiens Elongin-C Proteins 0.000 description 14
101000836005 Homo sapiens S-phase kinase-associated protein 1 Proteins 0.000 description 14
229940024606 amino acid Drugs 0.000 description 14
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 14
229920000768 polyamine Polymers 0.000 description 14
ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 14
PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 14
108091023037 Aptamer Proteins 0.000 description 13
OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 13
125000005647 linker group Chemical group 0.000 description 13
BHEHGFHLZIDTEH-UHFFFAOYSA-N 8-(difluoromethoxy)-2-ethoxy-7h-purine Chemical class CCOC1=NC=C2NC(OC(F)F)=NC2=N1 BHEHGFHLZIDTEH-UHFFFAOYSA-N 0.000 description 12
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 12
ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 12
229940088594 vitamin Drugs 0.000 description 12
229930003231 vitamin Natural products 0.000 description 12
235000013343 vitamin Nutrition 0.000 description 12
239000011782 vitamin Substances 0.000 description 12
108091006905 Human Serum Albumin Proteins 0.000 description 11
102000008100 Human Serum Albumin Human genes 0.000 description 11
235000001014 amino acid Nutrition 0.000 description 10
150000001413 amino acids Chemical class 0.000 description 10
235000019152 folic acid Nutrition 0.000 description 10
239000011724 folic acid Substances 0.000 description 10
238000001727 in vivo Methods 0.000 description 10
230000002401 inhibitory effect Effects 0.000 description 10
125000000547 substituted alkyl group Chemical group 0.000 description 10
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 9
MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 9
230000030279 gene silencing Effects 0.000 description 9
108091008104 nucleic acid aptamers Proteins 0.000 description 9
230000001225 therapeutic effect Effects 0.000 description 9
238000011282 treatment Methods 0.000 description 9
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 8
DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 8
229940124447 delivery agent Drugs 0.000 description 8
230000006870 function Effects 0.000 description 8
210000000056 organ Anatomy 0.000 description 8
150000003431 steroids Chemical class 0.000 description 8
238000001890 transfection Methods 0.000 description 8
IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 7
229910019142 PO4 Inorganic materials 0.000 description 7
102000006382 Ribonucleases Human genes 0.000 description 7
108010083644 Ribonucleases Proteins 0.000 description 7
125000002877 alkyl aryl group Chemical group 0.000 description 7
125000003710 aryl alkyl group Chemical group 0.000 description 7
230000008901 benefit Effects 0.000 description 7
230000015556 catabolic process Effects 0.000 description 7
125000002091 cationic group Chemical group 0.000 description 7
230000000875 corresponding effect Effects 0.000 description 7
238000006731 degradation reaction Methods 0.000 description 7
238000011161 development Methods 0.000 description 7
230000018109 developmental process Effects 0.000 description 7
229940014144 folate Drugs 0.000 description 7
239000010452 phosphate Substances 0.000 description 7
229940063673 spermidine Drugs 0.000 description 7
229940063675 spermine Drugs 0.000 description 7
238000006467 substitution reaction Methods 0.000 description 7
125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 7
UIYWFOZZIZEEKJ-XVFCMESISA-N 1-[(2r,3r,4r,5r)-3-fluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione Chemical class F[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 UIYWFOZZIZEEKJ-XVFCMESISA-N 0.000 description 6
JYVNKMPUWUYANG-UHFFFAOYSA-N 4-(difluoromethoxy)-2-ethoxypyrimidine Chemical class CCOC1=NC=CC(OC(F)F)=N1 JYVNKMPUWUYANG-UHFFFAOYSA-N 0.000 description 6
241000255581 Drosophila <fruit fly, genus> Species 0.000 description 6
NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 6
108010039918 Polylysine Proteins 0.000 description 6
244000097202 Rathbunia alamosensis Species 0.000 description 6
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 6
WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 6
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 6
UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 6
OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 6
PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 6
239000013604 expression vector Substances 0.000 description 6
125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 6
UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 6
230000001965 increasing effect Effects 0.000 description 6
230000007935 neutral effect Effects 0.000 description 6
150000003904 phospholipids Chemical class 0.000 description 6
229920000656 polylysine Polymers 0.000 description 6
229920001184 polypeptide Polymers 0.000 description 6
239000002243 precursor Substances 0.000 description 6
230000026447 protein localization Effects 0.000 description 6
102000005962 receptors Human genes 0.000 description 6
108020003175 receptors Proteins 0.000 description 6
101150054147 sina gene Proteins 0.000 description 6
238000013456 study Methods 0.000 description 6
239000005451 thionucleotide Substances 0.000 description 6
RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 6
230000032258 transport Effects 0.000 description 6
229940035893 uracil Drugs 0.000 description 6
NVZFZMCNALTPBY-XVFCMESISA-N 4-amino-1-[(2r,3r,4r,5r)-3-fluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](F)[C@H](O)[C@@H](CO)O1 NVZFZMCNALTPBY-XVFCMESISA-N 0.000 description 5
239000004475 Arginine Substances 0.000 description 5
206010007559 Cardiac failure congestive Diseases 0.000 description 5
102100023387 Endoribonuclease Dicer Human genes 0.000 description 5
101000907904 Homo sapiens Endoribonuclease Dicer Proteins 0.000 description 5
108010007622 LDL Lipoproteins Proteins 0.000 description 5
102000007330 LDL Lipoproteins Human genes 0.000 description 5
101710163270 Nuclease Proteins 0.000 description 5
125000000266 alpha-aminoacyl group Chemical group 0.000 description 5
125000004103 aminoalkyl group Chemical group 0.000 description 5
125000005122 aminoalkylamino group Chemical group 0.000 description 5
MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 description 5
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 5
235000009697 arginine Nutrition 0.000 description 5
229910052794 bromium Inorganic materials 0.000 description 5
150000001720 carbohydrates Chemical class 0.000 description 5
235000014633 carbohydrates Nutrition 0.000 description 5
230000004700 cellular uptake Effects 0.000 description 5
239000003153 chemical reaction reagent Substances 0.000 description 5
239000000460 chlorine Substances 0.000 description 5
229910052801 chlorine Inorganic materials 0.000 description 5
125000001651 cyanato group Chemical group [*]OC#N 0.000 description 5
239000003814 drug Substances 0.000 description 5
229910052731 fluorine Inorganic materials 0.000 description 5
229930182830 galactose Natural products 0.000 description 5
238000012226 gene silencing method Methods 0.000 description 5
125000000592 heterocycloalkyl group Chemical group 0.000 description 5
230000001976 improved effect Effects 0.000 description 5
238000012423 maintenance Methods 0.000 description 5
230000007246 mechanism Effects 0.000 description 5
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 5
108091070501 miRNA Proteins 0.000 description 5
229910052757 nitrogen Inorganic materials 0.000 description 5
125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 5
239000000816 peptidomimetic Substances 0.000 description 5
238000011160 research Methods 0.000 description 5
229910052717 sulfur Inorganic materials 0.000 description 5
239000004094 surface-active agent Substances 0.000 description 5
238000002560 therapeutic procedure Methods 0.000 description 5
230000003612 virological effect Effects 0.000 description 5
GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
SXUXMRMBWZCMEN-UHFFFAOYSA-N 2'-O-methyl uridine Natural products COC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 SXUXMRMBWZCMEN-UHFFFAOYSA-N 0.000 description 4
108700028369 Alleles Proteins 0.000 description 4
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 4
208000024172 Cardiovascular disease Diseases 0.000 description 4
108010078791 Carrier Proteins Proteins 0.000 description 4
241000196324 Embryophyta Species 0.000 description 4
241000282412 Homo Species 0.000 description 4
208000031226 Hyperlipidaemia Diseases 0.000 description 4
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
206010028980 Neoplasm Diseases 0.000 description 4
101710149951 Protein Tat Proteins 0.000 description 4
RADKZDMFGJYCBB-UHFFFAOYSA-N Pyridoxal Chemical compound CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 4
125000002015 acyclic group Chemical group 0.000 description 4
150000003838 adenosines Chemical class 0.000 description 4
238000004458 analytical method Methods 0.000 description 4
108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 4
230000027455 binding Effects 0.000 description 4
229960002685 biotin Drugs 0.000 description 4
235000020958 biotin Nutrition 0.000 description 4
239000011616 biotin Substances 0.000 description 4
201000011510 cancer Diseases 0.000 description 4
229920001577 copolymer Polymers 0.000 description 4
230000007423 decrease Effects 0.000 description 4
238000009826 distribution Methods 0.000 description 4
238000009472 formulation Methods 0.000 description 4
239000008101 lactose Substances 0.000 description 4
239000002502 liposome Substances 0.000 description 4
210000004185 liver Anatomy 0.000 description 4
210000004962 mammalian cell Anatomy 0.000 description 4
125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 4
102000042567 non-coding RNA Human genes 0.000 description 4
108091027963 non-coding RNA Proteins 0.000 description 4
102000054765 polymorphisms of proteins Human genes 0.000 description 4
230000032361 posttranscriptional gene silencing Effects 0.000 description 4
230000008569 process Effects 0.000 description 4
230000004044 response Effects 0.000 description 4
241000894007 species Species 0.000 description 4
JXNPEDYJTDQORS-HZJYTTRNSA-N (9Z,12Z)-octadecadien-1-ol Chemical compound CCCCC\C=C/C\C=C/CCCCCCCCO JXNPEDYJTDQORS-HZJYTTRNSA-N 0.000 description 3
NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 description 3
IQFYYKKMVGJFEH-BIIVOSGPSA-N 2'-deoxythymidine Natural products O=C1NC(=O)C(C)=CN1[C@@H]1O[C@@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-BIIVOSGPSA-N 0.000 description 3
PGYFLJKHWJVRMC-ZXRZDOCRSA-N 2-[4-[[(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]butoxy]-n,n-dimethyl-3-[(9z,12z)-octadeca-9,12-dienoxy]propan-1-amine Chemical compound C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OCCCCOC(CN(C)C)COCCCCCCCC\C=C/C\C=C/CCCCC)C1 PGYFLJKHWJVRMC-ZXRZDOCRSA-N 0.000 description 3
201000001320 Atherosclerosis Diseases 0.000 description 3
WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 3
102000004190 Enzymes Human genes 0.000 description 3
108090000790 Enzymes Proteins 0.000 description 3
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical group OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
102000003886 Glycoproteins Human genes 0.000 description 3
108090000288 Glycoproteins Proteins 0.000 description 3
208000035150 Hypercholesterolemia Diseases 0.000 description 3
UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 3
229930010555 Inosine Natural products 0.000 description 3
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 3
102000004856 Lectins Human genes 0.000 description 3
108090001090 Lectins Proteins 0.000 description 3
OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 3
108091060271 Small temporal RNA Proteins 0.000 description 3
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
239000002253 acid Substances 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
210000000170 cell membrane Anatomy 0.000 description 3
230000033077 cellular process Effects 0.000 description 3
208000026106 cerebrovascular disease Diseases 0.000 description 3
229940104302 cytosine Drugs 0.000 description 3
208000035475 disorder Diseases 0.000 description 3
229940079593 drug Drugs 0.000 description 3
229940088598 enzyme Drugs 0.000 description 3
229960000304 folic acid Drugs 0.000 description 3
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
238000010348 incorporation Methods 0.000 description 3
229960003786 inosine Drugs 0.000 description 3
102000006495 integrins Human genes 0.000 description 3
108010044426 integrins Proteins 0.000 description 3
230000003834 intracellular effect Effects 0.000 description 3
210000003734 kidney Anatomy 0.000 description 3
239000002523 lectin Substances 0.000 description 3
JXNPEDYJTDQORS-UHFFFAOYSA-N linoleyl alcohol Natural products CCCCCC=CCC=CCCCCCCCCO JXNPEDYJTDQORS-UHFFFAOYSA-N 0.000 description 3
210000005228 liver tissue Anatomy 0.000 description 3
210000004072 lung Anatomy 0.000 description 3
238000012544 monitoring process Methods 0.000 description 3
125000001624 naphthyl group Chemical group 0.000 description 3
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
XUYJLQHKOGNDPB-UHFFFAOYSA-N phosphonoacetic acid Chemical compound OC(=O)CP(O)(O)=O XUYJLQHKOGNDPB-UHFFFAOYSA-N 0.000 description 3
230000002062 proliferating effect Effects 0.000 description 3
UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 3
230000001105 regulatory effect Effects 0.000 description 3
230000006641 stabilisation Effects 0.000 description 3
238000011105 stabilization Methods 0.000 description 3
239000000126 substance Substances 0.000 description 3
125000000446 sulfanediyl group Chemical group *S* 0.000 description 3
229940104230 thymidine Drugs 0.000 description 3
229940113082 thymine Drugs 0.000 description 3
230000002103 transcriptional effect Effects 0.000 description 3
CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 3
ZGYYPTJWJBEXBC-QYYRPYCUSA-N (2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-4-fluoro-2-(hydroxymethyl)oxolan-3-ol Chemical class C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1F ZGYYPTJWJBEXBC-QYYRPYCUSA-N 0.000 description 2
WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 2
LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 2
FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
RFCQJGFZUQFYRF-UHFFFAOYSA-N 2'-O-Methylcytidine Natural products COC1C(O)C(CO)OC1N1C(=O)N=C(N)C=C1 RFCQJGFZUQFYRF-UHFFFAOYSA-N 0.000 description 2
SXUXMRMBWZCMEN-ZOQUXTDFSA-N 2'-O-methyluridine Chemical compound CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 SXUXMRMBWZCMEN-ZOQUXTDFSA-N 0.000 description 2
ZDTFMPXQUSBYRL-UUOKFMHZSA-N 2-Aminoadenosine Chemical compound C12=NC(N)=NC(N)=C2N=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O ZDTFMPXQUSBYRL-UUOKFMHZSA-N 0.000 description 2
UXUZARPLRQRNNX-DXTOWSMRSA-N 2-amino-9-[(2r,3r,4r,5r)-3-fluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purin-6-one Chemical class C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1F UXUZARPLRQRNNX-DXTOWSMRSA-N 0.000 description 2
LOJNBPNACKZWAI-UHFFFAOYSA-N 3-nitro-1h-pyrrole Chemical compound [O-][N+](=O)C=1C=CNC=1 LOJNBPNACKZWAI-UHFFFAOYSA-N 0.000 description 2
PJWBTAIPBFWVHX-FJGDRVTGSA-N 4-amino-1-[(2r,3s,4r,5r)-3-fluoro-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@](F)(O)[C@H](O)[C@@H](CO)O1 PJWBTAIPBFWVHX-FJGDRVTGSA-N 0.000 description 2
NVZFZMCNALTPBY-PXBUCIJWSA-N 4-amino-1-[(2r,3s,4r,5r)-3-fluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](F)[C@H](O)[C@@H](CO)O1 NVZFZMCNALTPBY-PXBUCIJWSA-N 0.000 description 2
OVONXEQGWXGFJD-UHFFFAOYSA-N 4-sulfanylidene-1h-pyrimidin-2-one Chemical compound SC=1C=CNC(=O)N=1 OVONXEQGWXGFJD-UHFFFAOYSA-N 0.000 description 2
LQLQRFGHAALLLE-UHFFFAOYSA-N 5-bromouracil Chemical compound BrC1=CNC(=O)NC1=O LQLQRFGHAALLLE-UHFFFAOYSA-N 0.000 description 2
KSNXJLQDQOIRIP-UHFFFAOYSA-N 5-iodouracil Chemical compound IC1=CNC(=O)NC1=O KSNXJLQDQOIRIP-UHFFFAOYSA-N 0.000 description 2
LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 2
OZFPSOBLQZPIAV-UHFFFAOYSA-N 5-nitro-1h-indole Chemical compound [O-][N+](=O)C1=CC=C2NC=CC2=C1 OZFPSOBLQZPIAV-UHFFFAOYSA-N 0.000 description 2
MSSXOMSJDRHRMC-UHFFFAOYSA-N 9H-purine-2,6-diamine Chemical compound NC1=NC(N)=C2NC=NC2=N1 MSSXOMSJDRHRMC-UHFFFAOYSA-N 0.000 description 2
229930024421 Adenine Natural products 0.000 description 2
GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
108091029845 Aminoallyl nucleotide Proteins 0.000 description 2
108700031308 Antennapedia Homeodomain Proteins 0.000 description 2
108020005544 Antisense RNA Proteins 0.000 description 2
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
102000004506 Blood Proteins Human genes 0.000 description 2
108010017384 Blood Proteins Proteins 0.000 description 2
239000002126 C01EB10 - Adenosine Substances 0.000 description 2
229920001661 Chitosan Polymers 0.000 description 2
150000008574 D-amino acids Chemical class 0.000 description 2
SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 2
229920002307 Dextran Polymers 0.000 description 2
108010042407 Endonucleases Proteins 0.000 description 2
PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 2
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
101000780643 Homo sapiens Protein argonaute-2 Proteins 0.000 description 2
206010020772 Hypertension Diseases 0.000 description 2
206010022489 Insulin Resistance Diseases 0.000 description 2
108010050904 Interferons Proteins 0.000 description 2
102000014150 Interferons Human genes 0.000 description 2
SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 2
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
SMEROWZSTRWXGI-UHFFFAOYSA-N Lithocholsaeure Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 SMEROWZSTRWXGI-UHFFFAOYSA-N 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
MRWXACSTFXYYMV-UHFFFAOYSA-N Nebularine Natural products OC1C(O)C(CO)OC1N1C2=NC=NC=C2N=C1 MRWXACSTFXYYMV-UHFFFAOYSA-N 0.000 description 2
241000244206 Nematoda Species 0.000 description 2
108700019961 Neoplasm Genes Proteins 0.000 description 2
102000048850 Neoplasm Genes Human genes 0.000 description 2
JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 2
229910004679 ONO2 Inorganic materials 0.000 description 2
208000008589 Obesity Diseases 0.000 description 2
KPKZJLCSROULON-QKGLWVMZSA-N Phalloidin Chemical compound N1C(=O)[C@@H]([C@@H](O)C)NC(=O)[C@H](C)NC(=O)[C@H](C[C@@](C)(O)CO)NC(=O)[C@H](C2)NC(=O)[C@H](C)NC(=O)[C@@H]3C[C@H](O)CN3C(=O)[C@@H]1CSC1=C2C2=CC=CC=C2N1 KPKZJLCSROULON-QKGLWVMZSA-N 0.000 description 2
229920001212 Poly(beta amino esters) Polymers 0.000 description 2
239000004372 Polyvinyl alcohol Substances 0.000 description 2
102100038955 Proprotein convertase subtilisin/kexin type 9 Human genes 0.000 description 2
108010029485 Protein Isoforms Proteins 0.000 description 2
102000001708 Protein Isoforms Human genes 0.000 description 2
102100034207 Protein argonaute-2 Human genes 0.000 description 2
AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
GMBQZIIUCVWOCD-WWASVFFGSA-N Sarsapogenine Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CC[C@H](O)C[C@H]4CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@H](C)CO1 GMBQZIIUCVWOCD-WWASVFFGSA-N 0.000 description 2
RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical group OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 2
208000032109 Transient ischaemic attack Diseases 0.000 description 2
208000036142 Viral infection Diseases 0.000 description 2
241000700605 Viruses Species 0.000 description 2
FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
229930003427 Vitamin E Natural products 0.000 description 2
230000001594 aberrant effect Effects 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
229960001138 acetylsalicylic acid Drugs 0.000 description 2
230000003213 activating effect Effects 0.000 description 2
230000004913 activation Effects 0.000 description 2
239000012190 activator Substances 0.000 description 2
229960000643 adenine Drugs 0.000 description 2
OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
229960005305 adenosine Drugs 0.000 description 2
210000000577 adipose tissue Anatomy 0.000 description 2
FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
239000000227 bioadhesive Substances 0.000 description 2
229960003150 bupivacaine Drugs 0.000 description 2
229960003677 chloroquine Drugs 0.000 description 2
WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 2
239000003184 complementary RNA Substances 0.000 description 2
208000029078 coronary artery disease Diseases 0.000 description 2
210000000805 cytoplasm Anatomy 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
229960002086 dextran Drugs 0.000 description 2
125000004386 diacrylate group Chemical group 0.000 description 2
239000001177 diphosphate Substances 0.000 description 2
102000010982 eIF-2 Kinase Human genes 0.000 description 2
108010037623 eIF-2 Kinase Proteins 0.000 description 2
238000004520 electroporation Methods 0.000 description 2
230000012202 endocytosis Effects 0.000 description 2
210000001163 endosome Anatomy 0.000 description 2
210000002889 endothelial cell Anatomy 0.000 description 2
230000002708 enhancing effect Effects 0.000 description 2
SUPCQIBBMFXVTL-UHFFFAOYSA-N ethyl 2-methylprop-2-enoate Chemical compound CCOC(=O)C(C)=C SUPCQIBBMFXVTL-UHFFFAOYSA-N 0.000 description 2
150000005699 fluoropyrimidines Chemical class 0.000 description 2
WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
238000004817 gas chromatography Methods 0.000 description 2
102000054766 genetic haplotypes Human genes 0.000 description 2
229940029575 guanosine Drugs 0.000 description 2
210000004209 hair Anatomy 0.000 description 2
BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
229960002885 histidine Drugs 0.000 description 2
229940079322 interferon Drugs 0.000 description 2
230000010468 interferon response Effects 0.000 description 2
SMEROWZSTRWXGI-HVATVPOCSA-N lithocholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 SMEROWZSTRWXGI-HVATVPOCSA-N 0.000 description 2
210000002540 macrophage Anatomy 0.000 description 2
230000003211 malignant effect Effects 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
239000012528 membrane Substances 0.000 description 2
208000030159 metabolic disease Diseases 0.000 description 2
LVWZTYCIRDMTEY-UHFFFAOYSA-N metamizole Chemical compound O=C1C(N(CS(O)(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 LVWZTYCIRDMTEY-UHFFFAOYSA-N 0.000 description 2
208000010125 myocardial infarction Diseases 0.000 description 2
MRWXACSTFXYYMV-FDDDBJFASA-N nebularine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC=C2N=C1 MRWXACSTFXYYMV-FDDDBJFASA-N 0.000 description 2
125000001893 nitrooxy group Chemical group [O-][N+](=O)O* 0.000 description 2
235000020824 obesity Nutrition 0.000 description 2
GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
210000003463 organelle Anatomy 0.000 description 2
210000004738 parenchymal cell Anatomy 0.000 description 2
239000002245 particle Substances 0.000 description 2
238000006366 phosphorylation reaction Methods 0.000 description 2
229920000724 poly(L-arginine) polymer Polymers 0.000 description 2
229920000962 poly(amidoamine) Polymers 0.000 description 2
229920001308 poly(aminoacid) Polymers 0.000 description 2
108010011110 polyarginine Proteins 0.000 description 2
229920002451 polyvinyl alcohol Polymers 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
239000001267 polyvinylpyrrolidone Substances 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
238000012545 processing Methods 0.000 description 2
ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 2
229960003581 pyridoxal Drugs 0.000 description 2
235000008164 pyridoxal Nutrition 0.000 description 2
239000011674 pyridoxal Substances 0.000 description 2
239000002718 pyrimidine nucleoside Substances 0.000 description 2
230000009711 regulatory function Effects 0.000 description 2
NSKGQURZWSPSBC-VVPCINPTSA-N ribostamycin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](N)C[C@@H]1N NSKGQURZWSPSBC-VVPCINPTSA-N 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
210000003491 skin Anatomy 0.000 description 2
239000007787 solid Substances 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
230000009466 transformation Effects 0.000 description 2
201000010875 transient cerebral ischemia Diseases 0.000 description 2
230000009752 translational inhibition Effects 0.000 description 2
239000001226 triphosphate Substances 0.000 description 2
208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
101150003485 unc-22 gene Proteins 0.000 description 2
XUARCIYIVXVTAE-ZAPOICBTSA-N uvaol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(CO)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C XUARCIYIVXVTAE-ZAPOICBTSA-N 0.000 description 2
230000009385 viral infection Effects 0.000 description 2
235000019155 vitamin A Nutrition 0.000 description 2
239000011719 vitamin A Substances 0.000 description 2
235000019165 vitamin E Nutrition 0.000 description 2
229940046009 vitamin E Drugs 0.000 description 2
239000011709 vitamin E Substances 0.000 description 2
229940045997 vitamin a Drugs 0.000 description 2
NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical group CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical group C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 description 1
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
KJTPWUVVLPCPJD-AUWJEWJLSA-N (2z)-7-amino-2-[(4-hydroxy-3,5-dimethylphenyl)methylidene]-5,6-dimethoxy-3h-inden-1-one Chemical compound O=C1C=2C(N)=C(OC)C(OC)=CC=2C\C1=C\C1=CC(C)=C(O)C(C)=C1 KJTPWUVVLPCPJD-AUWJEWJLSA-N 0.000 description 1
BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
FYADHXFMURLYQI-UHFFFAOYSA-N 1,2,4-triazine Chemical class C1=CN=NC=N1 FYADHXFMURLYQI-UHFFFAOYSA-N 0.000 description 1
ZIZMDHZLHJBNSQ-UHFFFAOYSA-N 1,2-dihydrophenazine Chemical compound C1=CC=C2N=C(C=CCC3)C3=NC2=C1 ZIZMDHZLHJBNSQ-UHFFFAOYSA-N 0.000 description 1
LKUDPHPHKOZXCD-UHFFFAOYSA-N 1,3,5-trimethoxybenzene Chemical compound COC1=CC(OC)=CC(OC)=C1 LKUDPHPHKOZXCD-UHFFFAOYSA-N 0.000 description 1
YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Chemical group OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 1
SGKGZYGMLGVQHP-ZOQUXTDFSA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-methylpyrimidine-2,4-dione Chemical compound CC1=CC(=O)NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 SGKGZYGMLGVQHP-ZOQUXTDFSA-N 0.000 description 1
UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
MZMNEDXVUJLQAF-UHFFFAOYSA-N 1-o-tert-butyl 2-o-methyl 4-hydroxypyrrolidine-1,2-dicarboxylate Chemical compound COC(=O)C1CC(O)CN1C(=O)OC(C)(C)C MZMNEDXVUJLQAF-UHFFFAOYSA-N 0.000 description 1
TZMSYXZUNZXBOL-UHFFFAOYSA-N 10H-phenoxazine Chemical compound C1=CC=C2NC3=CC=CC=C3OC2=C1 TZMSYXZUNZXBOL-UHFFFAOYSA-N 0.000 description 1
NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 1
102000007445 2',5'-Oligoadenylate Synthetase Human genes 0.000 description 1
108010086241 2',5'-Oligoadenylate Synthetase Proteins 0.000 description 1
CKTSBUTUHBMZGZ-SHYZEUOFSA-N 2'‐deoxycytidine Chemical group O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 CKTSBUTUHBMZGZ-SHYZEUOFSA-N 0.000 description 1
VEPOHXYIFQMVHW-XOZOLZJESA-N 2,3-dihydroxybutanedioic acid (2S,3S)-3,4-dimethyl-2-phenylmorpholine Chemical compound OC(C(O)C(O)=O)C(O)=O.C[C@H]1[C@@H](OCCN1C)c1ccccc1 VEPOHXYIFQMVHW-XOZOLZJESA-N 0.000 description 1
AZUHIVLOSAPWDM-UHFFFAOYSA-N 2-(1h-imidazol-2-yl)-1h-imidazole Chemical compound C1=CNC(C=2NC=CN=2)=N1 AZUHIVLOSAPWDM-UHFFFAOYSA-N 0.000 description 1
102100027962 2-5A-dependent ribonuclease Human genes 0.000 description 1
108010000834 2-5A-dependent ribonuclease Proteins 0.000 description 1
MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
WAVYAFBQOXCGSZ-UHFFFAOYSA-N 2-fluoropyrimidine Chemical class FC1=NC=CC=N1 WAVYAFBQOXCGSZ-UHFFFAOYSA-N 0.000 description 1
KMEBCRWKZZSRRT-UHFFFAOYSA-N 2-methyl-7h-purine Chemical class CC1=NC=C2NC=NC2=N1 KMEBCRWKZZSRRT-UHFFFAOYSA-N 0.000 description 1
VPLZGVOSFFCKFC-UHFFFAOYSA-N 3-methyluracil Chemical compound CN1C(=O)C=CNC1=O VPLZGVOSFFCKFC-UHFFFAOYSA-N 0.000 description 1
HIAJCGFYHIANNA-QIZZZRFXSA-N 3b-Hydroxy-5-cholenoic acid Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@@H](CCC(O)=O)C)[C@@]1(C)CC2 HIAJCGFYHIANNA-QIZZZRFXSA-N 0.000 description 1
GCNTZFIIOFTKIY-UHFFFAOYSA-N 4-hydroxypyridine Chemical compound OC1=CC=NC=C1 GCNTZFIIOFTKIY-UHFFFAOYSA-N 0.000 description 1
ZAYHVCMSTBRABG-UHFFFAOYSA-N 5-Methylcytidine Natural products O=C1N=C(N)C(C)=CN1C1C(O)C(O)C(CO)O1 ZAYHVCMSTBRABG-UHFFFAOYSA-N 0.000 description 1
AGFIRQJZCNVMCW-UAKXSSHOSA-N 5-bromouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 AGFIRQJZCNVMCW-UAKXSSHOSA-N 0.000 description 1
ZAYHVCMSTBRABG-JXOAFFINSA-N 5-methylcytidine Chemical compound O=C1N=C(N)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 ZAYHVCMSTBRABG-JXOAFFINSA-N 0.000 description 1
108091027075 5S-rRNA precursor Proteins 0.000 description 1
JBCNZZKORZNYML-UHFFFAOYSA-N 7h-purine;trihydroxy(sulfanylidene)-$l^{5}-phosphane Chemical compound OP(O)(O)=S.C1=NC=C2NC=NC2=N1 JBCNZZKORZNYML-UHFFFAOYSA-N 0.000 description 1
241000589158 Agrobacterium Species 0.000 description 1
206010002383 Angina Pectoris Diseases 0.000 description 1
206010003210 Arteriosclerosis Diseases 0.000 description 1
206010003658 Atrial Fibrillation Diseases 0.000 description 1
229940122361 Bisphosphonate Drugs 0.000 description 1
229920002101 Chitin Polymers 0.000 description 1
239000004380 Cholic acid Substances 0.000 description 1
108010077544 Chromatin Proteins 0.000 description 1
108091026890 Coding region Proteins 0.000 description 1
239000004971 Cross linker Substances 0.000 description 1
MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
108010069514 Cyclic Peptides Proteins 0.000 description 1
102000001189 Cyclic Peptides Human genes 0.000 description 1
229920000858 Cyclodextrin Polymers 0.000 description 1
UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
NBSCHQHZLSJFNQ-QTVWNMPRSA-N D-Mannose-6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@@H]1O NBSCHQHZLSJFNQ-QTVWNMPRSA-N 0.000 description 1
CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
KVSNMTUIMXZPLU-UHFFFAOYSA-N D:A-friedo-oleanane Natural products CC12CCC3(C)C4CC(C)(C)CCC4(C)CCC3(C)C2CCC2(C)C1CCCC2C KVSNMTUIMXZPLU-UHFFFAOYSA-N 0.000 description 1
NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
CKTSBUTUHBMZGZ-UHFFFAOYSA-N Deoxycytidine Natural products O=C1N=C(N)C=CN1C1OC(CO)C(O)C1 CKTSBUTUHBMZGZ-UHFFFAOYSA-N 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
102100031780 Endonuclease Human genes 0.000 description 1
102000004533 Endonucleases Human genes 0.000 description 1
JUUHNUPNMCGYDT-UHFFFAOYSA-N Friedelin Natural products CC1CC2C(C)(CCC3(C)C4CC(C)(C)CCC4(C)CCC23C)C5CCC(=O)C(C)C15 JUUHNUPNMCGYDT-UHFFFAOYSA-N 0.000 description 1
241000233866 Fungi Species 0.000 description 1
102000006395 Globulins Human genes 0.000 description 1
108010044091 Globulins Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
206010019280 Heart failures Diseases 0.000 description 1
241000700721 Hepatitis B virus Species 0.000 description 1
108700005087 Homeobox Genes Proteins 0.000 description 1
241000282414 Homo sapiens Species 0.000 description 1
101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 description 1
108010070875 Human Immunodeficiency Virus tat Gene Products Proteins 0.000 description 1
241000725303 Human immunodeficiency virus Species 0.000 description 1
208000001021 Hyperlipoproteinemia Type I Diseases 0.000 description 1
208000000563 Hyperlipoproteinemia Type II Diseases 0.000 description 1
201000010252 Hyperlipoproteinemia Type III Diseases 0.000 description 1
208000026350 Inborn Genetic disease Diseases 0.000 description 1
108010047761 Interferon-alpha Proteins 0.000 description 1
102000006992 Interferon-alpha Human genes 0.000 description 1
229920001202 Inulin Polymers 0.000 description 1
CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
208000023768 LCAT deficiency Diseases 0.000 description 1
208000003465 Lecithin Cholesterol Acyltransferase Deficiency Diseases 0.000 description 1
239000012097 Lipofectamine 2000 Substances 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
108010007013 Melanocyte-Stimulating Hormones Proteins 0.000 description 1
108010090054 Membrane Glycoproteins Proteins 0.000 description 1
102000012750 Membrane Glycoproteins Human genes 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
102000029749 Microtubule Human genes 0.000 description 1
108091022875 Microtubule Proteins 0.000 description 1
102100023482 Mitogen-activated protein kinase 14 Human genes 0.000 description 1
102000015728 Mucins Human genes 0.000 description 1
108010063954 Mucins Proteins 0.000 description 1
125000003047 N-acetyl group Chemical group 0.000 description 1
241000221960 Neurospora Species 0.000 description 1
KYRVNWMVYQXFEU-UHFFFAOYSA-N Nocodazole Chemical compound C1=C2NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=CS1 KYRVNWMVYQXFEU-UHFFFAOYSA-N 0.000 description 1
235000021314 Palmitic acid Nutrition 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
208000018262 Peripheral vascular disease Diseases 0.000 description 1
108010009711 Phalloidine Proteins 0.000 description 1
PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
241000425347 Phyla <beetle> Species 0.000 description 1
108010069381 Platelet Endothelial Cell Adhesion Molecule-1 Proteins 0.000 description 1
102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 1
239000004952 Polyamide Substances 0.000 description 1
108010020346 Polyglutamic Acid Proteins 0.000 description 1
239000004721 Polyphenylene oxide Substances 0.000 description 1
108010022249 Proprotein Convertase 9 Proteins 0.000 description 1
108010007568 Protamines Proteins 0.000 description 1
102000007327 Protamines Human genes 0.000 description 1
108010067787 Proteoglycans Proteins 0.000 description 1
102000016611 Proteoglycans Human genes 0.000 description 1
101000781681 Protobothrops flavoviridis Disintegrin triflavin Proteins 0.000 description 1
239000004373 Pullulan Substances 0.000 description 1
229920001218 Pullulan Polymers 0.000 description 1
108010007100 Pulmonary Surfactant-Associated Protein A Proteins 0.000 description 1
102000007615 Pulmonary Surfactant-Associated Protein A Human genes 0.000 description 1
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
108091030071 RNAI Proteins 0.000 description 1
241000269435 Rana <genus> Species 0.000 description 1
108010057163 Ribonuclease III Proteins 0.000 description 1
102000003661 Ribonuclease III Human genes 0.000 description 1
241000700584 Simplexvirus Species 0.000 description 1
102000039471 Small Nuclear RNA Human genes 0.000 description 1
241000272534 Struthio camelus Species 0.000 description 1
101710137500 T7 RNA polymerase Proteins 0.000 description 1
101710192266 Tegument protein VP22 Proteins 0.000 description 1
108010061174 Thyrotropin Proteins 0.000 description 1
102000011923 Thyrotropin Human genes 0.000 description 1
RTMWIZOXNKJHRE-UHFFFAOYSA-N Tigogenin Natural products CC1COC2CC(C)(OC12)C3CCC4C5CCC6CC(O)CCC6(C)C5CCC34C RTMWIZOXNKJHRE-UHFFFAOYSA-N 0.000 description 1
102100039390 Toll-like receptor 7 Human genes 0.000 description 1
102000040945 Transcription factor Human genes 0.000 description 1
108091023040 Transcription factor Proteins 0.000 description 1
102000004338 Transferrin Human genes 0.000 description 1
108090000901 Transferrin Proteins 0.000 description 1
DWCSNWXARWMZTG-UHFFFAOYSA-N Trigonegenin A Natural products CC1C(C2(CCC3C4(C)CCC(O)C=C4CCC3C2C2)C)C2OC11CCC(C)CO1 DWCSNWXARWMZTG-UHFFFAOYSA-N 0.000 description 1
206010060749 Type I hyperlipidaemia Diseases 0.000 description 1
206010045254 Type II hyperlipidaemia Diseases 0.000 description 1
206010060751 Type III hyperlipidaemia Diseases 0.000 description 1
206010060753 Type IV hyperlipidaemia Diseases 0.000 description 1
206010060755 Type V hyperlipidaemia Diseases 0.000 description 1
108091023045 Untranslated Region Proteins 0.000 description 1
229910052770 Uranium Inorganic materials 0.000 description 1
JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
108010087302 Viral Structural Proteins Proteins 0.000 description 1
229930003779 Vitamin B12 Natural products 0.000 description 1
229930003448 Vitamin K Natural products 0.000 description 1
239000008351 acetate buffer Substances 0.000 description 1
XVIYCJDWYLJQBG-UHFFFAOYSA-N acetic acid;adamantane Chemical compound CC(O)=O.C1C(C2)CC3CC1CC2C3 XVIYCJDWYLJQBG-UHFFFAOYSA-N 0.000 description 1
QDFXXKCVJKJXMP-UHFFFAOYSA-N acridine;1h-imidazole Chemical compound C1=CNC=N1.C1=CC=CC2=CC3=CC=CC=C3N=C21 QDFXXKCVJKJXMP-UHFFFAOYSA-N 0.000 description 1
150000001251 acridines Chemical class 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
238000013019 agitation Methods 0.000 description 1
125000003172 aldehyde group Chemical group 0.000 description 1
239000002168 alkylating agent Substances 0.000 description 1
229940100198 alkylating agent Drugs 0.000 description 1
150000001409 amidines Chemical class 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
125000003277 amino group Chemical class 0.000 description 1
230000019552 anatomical structure morphogenesis Effects 0.000 description 1
229960003473 androstanolone Drugs 0.000 description 1
238000010171 animal model Methods 0.000 description 1
125000000129 anionic group Chemical group 0.000 description 1
230000003466 anti-cipated effect Effects 0.000 description 1
239000003443 antiviral agent Substances 0.000 description 1
206010002906 aortic stenosis Diseases 0.000 description 1
238000013459 approach Methods 0.000 description 1
206010003119 arrhythmia Diseases 0.000 description 1
230000006793 arrhythmia Effects 0.000 description 1
208000011775 arteriosclerosis disease Diseases 0.000 description 1
229960005261 aspartic acid Drugs 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
108010028263 bacteriophage T3 RNA polymerase Proteins 0.000 description 1
MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
239000003613 bile acid Substances 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
239000012620 biological material Substances 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
150000004663 bisphosphonates Chemical class 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
210000002449 bone cell Anatomy 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
230000002032 cellular defenses Effects 0.000 description 1
230000036755 cellular response Effects 0.000 description 1
229960000541 cetyl alcohol Drugs 0.000 description 1
235000019416 cholic acid Nutrition 0.000 description 1
BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
229960002471 cholic acid Drugs 0.000 description 1
210000003483 chromatin Anatomy 0.000 description 1
AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
230000021615 conjugation Effects 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
239000003431 cross linking reagent Substances 0.000 description 1
JVHIPYJQMFNCEK-UHFFFAOYSA-N cytochalasin Natural products N1C(=O)C2(C(C=CC(C)CC(C)CC=C3)OC(C)=O)C3C(O)C(=C)C(C)C2C1CC1=CC=CC=C1 JVHIPYJQMFNCEK-UHFFFAOYSA-N 0.000 description 1
ZMAODHOXRBLOQO-UHFFFAOYSA-N cytochalasin-A Natural products N1C(=O)C23OC(=O)C=CC(=O)CCCC(C)CC=CC3C(O)C(=C)C(C)C2C1CC1=CC=CC=C1 ZMAODHOXRBLOQO-UHFFFAOYSA-N 0.000 description 1
210000004292 cytoskeleton Anatomy 0.000 description 1
210000000172 cytosol Anatomy 0.000 description 1
231100000135 cytotoxicity Toxicity 0.000 description 1
230000003013 cytotoxicity Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000005860 defense response to virus Effects 0.000 description 1
239000000412 dendrimer Substances 0.000 description 1
229920000736 dendritic polymer Polymers 0.000 description 1
KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
ZPTBLXKRQACLCR-XVFCMESISA-N dihydrouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)CC1 ZPTBLXKRQACLCR-XVFCMESISA-N 0.000 description 1
125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
WQLVFSAGQJTQCK-VKROHFNGSA-N diosgenin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CC[C@H](O)CC4=CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 WQLVFSAGQJTQCK-VKROHFNGSA-N 0.000 description 1
WQLVFSAGQJTQCK-UHFFFAOYSA-N diosgenin Natural products CC1C(C2(CCC3C4(C)CCC(O)CC4=CCC3C2C2)C)C2OC11CCC(C)CO1 WQLVFSAGQJTQCK-UHFFFAOYSA-N 0.000 description 1
NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 description 1
XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
235000011180 diphosphates Nutrition 0.000 description 1
230000002222 downregulating effect Effects 0.000 description 1
238000009509 drug development Methods 0.000 description 1
238000007877 drug screening Methods 0.000 description 1
239000000975 dye Substances 0.000 description 1
230000009881 electrostatic interaction Effects 0.000 description 1
239000002158 endotoxin Substances 0.000 description 1
XCDQFROEGGNAER-PFOIMGGJSA-N epi-Friedelanol Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)C(C)(C)CC[C@]1(C)CC[C@]2(C)[C@H]4CC[C@@]1(C)[C@H]3CC[C@H](O)[C@@H]1C XCDQFROEGGNAER-PFOIMGGJSA-N 0.000 description 1
FWTBRZMBHIYQSW-UHFFFAOYSA-N epifriedelanol Natural products CC1C(O)C(O)CC2C1(C)CCC3C2(C)CCC4(C)C5CC(C)(C)CCC5(C)C(O)CC34C FWTBRZMBHIYQSW-UHFFFAOYSA-N 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
239000000835 fiber Substances 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
238000005755 formation reaction Methods 0.000 description 1
OFMXGFHWLZPCFL-SVRPQWSVSA-N friedelin Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)C(C)(C)CC[C@]1(C)CC[C@]2(C)[C@H]4CC[C@@]1(C)[C@H]3CCC(=O)[C@@H]1C OFMXGFHWLZPCFL-SVRPQWSVSA-N 0.000 description 1
MFVJCHSUSSRHRH-UHFFFAOYSA-N friedeline Natural products CC1(C)CCC2(C)CCC3C4(C)CCC5C(C)(C)C(=O)CCC5(C)C4CCC3(C)C2C1 MFVJCHSUSSRHRH-UHFFFAOYSA-N 0.000 description 1
230000005714 functional activity Effects 0.000 description 1
ZXQYGBMAQZUVMI-GCMPRSNUSA-N gamma-cyhalothrin Chemical compound CC1(C)[C@@H](\C=C(/Cl)C(F)(F)F)[C@H]1C(=O)O[C@H](C#N)C1=CC=CC(OC=2C=CC=CC=2)=C1 ZXQYGBMAQZUVMI-GCMPRSNUSA-N 0.000 description 1
229920000370 gamma-poly(glutamate) polymer Polymers 0.000 description 1
238000001476 gene delivery Methods 0.000 description 1
238000001415 gene therapy Methods 0.000 description 1
102000054767 gene variant Human genes 0.000 description 1
208000016361 genetic disease Diseases 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
229960002442 glucosamine Drugs 0.000 description 1
239000008103 glucose Substances 0.000 description 1
229960002989 glutamic acid Drugs 0.000 description 1
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
229910052737 gold Inorganic materials 0.000 description 1
239000010931 gold Substances 0.000 description 1
ZRALSGWEFCBTJO-UHFFFAOYSA-N guanidine group Chemical group NC(=N)N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 1
210000002064 heart cell Anatomy 0.000 description 1
210000005003 heart tissue Anatomy 0.000 description 1
GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 1
229960001340 histamine Drugs 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
108091008039 hormone receptors Proteins 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
229920002674 hyaluronan Polymers 0.000 description 1
229960003160 hyaluronic acid Drugs 0.000 description 1
238000009396 hybridization Methods 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
208000020887 hyperlipoproteinemia type 3 Diseases 0.000 description 1
208000000522 hyperlipoproteinemia type IV Diseases 0.000 description 1
150000002460 imidazoles Chemical class 0.000 description 1
125000002883 imidazolyl group Chemical group 0.000 description 1
125000000879 imine group Chemical group 0.000 description 1
230000028993 immune response Effects 0.000 description 1
230000003308 immunostimulating effect Effects 0.000 description 1
230000006698 induction Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000004941 influx Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
230000015788 innate immune response Effects 0.000 description 1
230000010354 integration Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
239000000138 intercalating agent Substances 0.000 description 1
210000003963 intermediate filament Anatomy 0.000 description 1
JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
229940029339 inulin Drugs 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
210000001630 jejunum Anatomy 0.000 description 1
DDVBPZROPPMBLW-ZJBINBEQSA-N latrunculin a Chemical compound C([C@H]1[C@@]2(O)C[C@H]3C[C@H](O2)CC[C@@H](/C=C\C=C/CC\C(C)=C/C(=O)O3)C)SC(=O)N1 DDVBPZROPPMBLW-ZJBINBEQSA-N 0.000 description 1
DDVBPZROPPMBLW-UHFFFAOYSA-N latrunculin-A Natural products O1C(=O)C=C(C)CCC=CC=CC(C)CCC(O2)CC1CC2(O)C1CSC(=O)N1 DDVBPZROPPMBLW-UHFFFAOYSA-N 0.000 description 1
108020001756 ligand binding domains Proteins 0.000 description 1
150000002634 lipophilic molecules Chemical class 0.000 description 1
229920006008 lipopolysaccharide Polymers 0.000 description 1
210000005229 liver cell Anatomy 0.000 description 1
238000011068 loading method Methods 0.000 description 1
231100000053 low toxicity Toxicity 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
239000006166 lysate Substances 0.000 description 1
125000002960 margaryl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
229940041616 menthol Drugs 0.000 description 1
230000011987 methylation Effects 0.000 description 1
238000007069 methylation reaction Methods 0.000 description 1
210000003632 microfilament Anatomy 0.000 description 1
238000000520 microinjection Methods 0.000 description 1
210000004688 microtubule Anatomy 0.000 description 1
229960004857 mitomycin Drugs 0.000 description 1
230000037230 mobility Effects 0.000 description 1
239000003607 modifier Substances 0.000 description 1
150000004712 monophosphates Chemical class 0.000 description 1
WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 1
QNILTEGFHQSKFF-UHFFFAOYSA-N n-propan-2-ylprop-2-enamide Chemical compound CC(C)NC(=O)C=C QNILTEGFHQSKFF-UHFFFAOYSA-N 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
210000000440 neutrophil Anatomy 0.000 description 1
229950006344 nocodazole Drugs 0.000 description 1
QTNLALDFXILRQO-UHFFFAOYSA-N nonadecane-1,2,3-triol Chemical group CCCCCCCCCCCCCCCCC(O)C(O)CO QTNLALDFXILRQO-UHFFFAOYSA-N 0.000 description 1
230000000269 nucleophilic effect Effects 0.000 description 1
125000003835 nucleoside group Chemical group 0.000 description 1
210000004940 nucleus Anatomy 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
230000009437 off-target effect Effects 0.000 description 1
229940055577 oleyl alcohol Drugs 0.000 description 1
XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
MCYTYTUNNNZWOK-LCLOTLQISA-N penetratin Chemical compound C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CC=CC=C1 MCYTYTUNNNZWOK-LCLOTLQISA-N 0.000 description 1
230000035515 penetration Effects 0.000 description 1
239000000863 peptide conjugate Substances 0.000 description 1
230000002974 pharmacogenomic effect Effects 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
239000012071 phase Substances 0.000 description 1
150000004713 phosphodiesters Chemical class 0.000 description 1
LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical class [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 description 1
230000026731 phosphorylation Effects 0.000 description 1
SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
210000005134 plasmacytoid dendritic cell Anatomy 0.000 description 1
239000013612 plasmid Substances 0.000 description 1
229920002627 poly(phosphazenes) Polymers 0.000 description 1
229920002647 polyamide Polymers 0.000 description 1
108010064470 polyaspartate Proteins 0.000 description 1
125000005575 polycyclic aromatic hydrocarbon group Chemical group 0.000 description 1
229920000570 polyether Polymers 0.000 description 1
229920002704 polyhistidine Polymers 0.000 description 1
229920000166 polytrimethylene carbonate Chemical group 0.000 description 1
229920002635 polyurethane Polymers 0.000 description 1
239000004814 polyurethane Substances 0.000 description 1
150000004032 porphyrins Chemical class 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
230000002265 prevention Effects 0.000 description 1
150000003141 primary amines Chemical group 0.000 description 1
239000000047 product Substances 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
MWWATHDPGQKSAR-UHFFFAOYSA-N propyne Chemical compound CC#C MWWATHDPGQKSAR-UHFFFAOYSA-N 0.000 description 1
229940048914 protamine Drugs 0.000 description 1
210000001938 protoplast Anatomy 0.000 description 1
235000019423 pullulan Nutrition 0.000 description 1
239000002212 purine nucleoside Substances 0.000 description 1
JUGKVSNCOWXSFE-UHFFFAOYSA-N pyrimidine;trihydroxy(sulfanylidene)-$l^{5}-phosphane Chemical compound OP(O)(O)=S.C1=CN=CN=C1 JUGKVSNCOWXSFE-UHFFFAOYSA-N 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
125000006853 reporter group Chemical group 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
235000019192 riboflavin Nutrition 0.000 description 1
239000002151 riboflavin Substances 0.000 description 1
229960002477 riboflavin Drugs 0.000 description 1
DWRXFEITVBNRMK-JXOAFFINSA-N ribothymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 DWRXFEITVBNRMK-JXOAFFINSA-N 0.000 description 1
150000003839 salts Chemical group 0.000 description 1
COFLCBMDHTVQRA-UHFFFAOYSA-N sapphyrin Chemical compound N1C(C=2NC(C=C3N=C(C=C4NC(=C5)C=C4)C=C3)=CC=2)=CC=C1C=C1C=CC5=N1 COFLCBMDHTVQRA-UHFFFAOYSA-N 0.000 description 1
HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
238000012216 screening Methods 0.000 description 1
238000002864 sequence alignment Methods 0.000 description 1
125000005629 sialic acid group Chemical group 0.000 description 1
230000011664 signaling Effects 0.000 description 1
HBMJWWWQQXIZIP-UHFFFAOYSA-N silicon carbide Chemical compound [Si+]#[C-] HBMJWWWQQXIZIP-UHFFFAOYSA-N 0.000 description 1
229910010271 silicon carbide Inorganic materials 0.000 description 1
108091029842 small nuclear ribonucleic acid Proteins 0.000 description 1
210000000329 smooth muscle myocyte Anatomy 0.000 description 1
125000006850 spacer group Chemical group 0.000 description 1
229940012831 stearyl alcohol Drugs 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
239000011593 sulfur Substances 0.000 description 1
230000001629 suppression Effects 0.000 description 1
230000008961 swelling Effects 0.000 description 1
RJVBVECTCMRNFG-ANKJNSLFSA-N swinholide a Chemical compound C1[C@H](OC)C[C@H](C)O[C@H]1CC[C@H](C)[C@H](O)[C@H](C)[C@@H]1[C@@H](C)[C@H](O)C[C@H](O)[C@H](C)[C@@H](OC)C[C@H](CC=C2)O[C@@H]2C[C@@H](O)C/C=C(\C)/C=C/C(=O)O[C@H]([C@@H](C)[C@@H](O)[C@@H](C)CC[C@@H]2O[C@@H](C)C[C@H](C2)OC)[C@@H](C)[C@H](O)C[C@H](O)[C@H](C)[C@@H](OC)C[C@H](CC=C2)O[C@@H]2C[C@@H](O)C/C=C(\C)/C=C/C(=O)O1 RJVBVECTCMRNFG-ANKJNSLFSA-N 0.000 description 1
GDACDJNQZCXLNU-UHFFFAOYSA-N swinholide-A Natural products C1C(OC)CC(C)OC1CCC(C)C(O)C(C)C1C(C)C(O)CC(O)C(C)C(OC)CC(CC=C2)OC2CC(O)CC=C(C)C=CC(=O)O1 GDACDJNQZCXLNU-UHFFFAOYSA-N 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
229920001059 synthetic polymer Polymers 0.000 description 1
150000003505 terpenes Chemical class 0.000 description 1
235000007586 terpenes Nutrition 0.000 description 1
TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
XXYIANZGUOSQHY-XLPZGREQSA-N thymidine 3'-monophosphate Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](OP(O)(O)=O)C1 XXYIANZGUOSQHY-XLPZGREQSA-N 0.000 description 1
229960000874 thyrotropin Drugs 0.000 description 1
230000001748 thyrotropin Effects 0.000 description 1
230000001526 topogenic effect Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
230000035897 transcription Effects 0.000 description 1
238000013518 transcription Methods 0.000 description 1
238000010361 transduction Methods 0.000 description 1
230000026683 transduction Effects 0.000 description 1
238000012546 transfer Methods 0.000 description 1
239000012581 transferrin Substances 0.000 description 1
230000009261 transgenic effect Effects 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
235000011178 triphosphate Nutrition 0.000 description 1
125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
150000003648 triterpenes Chemical class 0.000 description 1
241001529453 unidentified herpesvirus Species 0.000 description 1
DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
229940045145 uridine Drugs 0.000 description 1
SYFNOXYZEIYOSE-UHFFFAOYSA-N uvaol Natural products CC1CCC2(O)CCC3(C)C(=CCC4(C)C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C SYFNOXYZEIYOSE-UHFFFAOYSA-N 0.000 description 1
238000010200 validation analysis Methods 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
229960003048 vinblastine Drugs 0.000 description 1
JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
229960004528 vincristine Drugs 0.000 description 1
OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
235000019156 vitamin B Nutrition 0.000 description 1
239000011720 vitamin B Substances 0.000 description 1
235000019163 vitamin B12 Nutrition 0.000 description 1
239000011715 vitamin B12 Substances 0.000 description 1
235000019168 vitamin K Nutrition 0.000 description 1
239000011712 vitamin K Substances 0.000 description 1
150000003721 vitamin K derivatives Chemical class 0.000 description 1
150000003722 vitamin derivatives Chemical class 0.000 description 1
229940046010 vitamin k Drugs 0.000 description 1
229920003169 water-soluble polymer Polymers 0.000 description 1
SFVVQRJOGUKCEG-OPQSFPLASA-N β-MSH Chemical compound C1C[C@@H](O)[C@H]2C(COC(=O)[C@@](O)([C@@H](C)O)C(C)C)=CCN21 SFVVQRJOGUKCEG-OPQSFPLASA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Cardiology (AREA)
Diabetes (AREA)
Heart & Thoracic Surgery (AREA)
Genetics & Genomics (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Obesity (AREA)
Molecular Biology (AREA)
Biotechnology (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Biophysics (AREA)
Plant Pathology (AREA)
Urology & Nephrology (AREA)
Physics & Mathematics (AREA)
Endocrinology (AREA)
Hospice & Palliative Care (AREA)
Virology (AREA)
Vascular Medicine (AREA)
Microbiology (AREA)
Child & Adolescent Psychology (AREA)
Emergency Medicine (AREA)
Biochemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

AU2007275365A 2006-07-17 2007-07-17 RNA interference mediated inhibition of Proprotein Convertase Subtilisin Kexin 9 (PCSK9) gene expression using short interfering nucleic acid (siNA) Abandoned AU2007275365A1 (en)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US11/487,788		2006-07-17
US11/487,788 US20070173473A1 (en)	2001-05-18	2006-07-17	RNA interference mediated inhibition of proprotein convertase subtilisin Kexin 9 (PCSK9) gene expression using short interfering nucleic acid (siNA)
US86136906P	2006-11-28	2006-11-28
US60/861,369		2006-11-28
PCT/US2007/073723 WO2008011431A2 (fr)	2006-07-17	2007-07-17	INHIBITION MÉDIÉE PAR UNE INTERFÉRENCE DE L'ARN DE L'EXPRESSION DU GÈNE DE LA PROPROTÉINE CONVERTASE SUBTILISINE KEXINE DE TYPE 9 (PCSK9) AU MOYEN DE PETITS ACIDES NUCLÉIQUES INTERFÉRANTS(ANsi)

Publications (1)

Publication Number	Publication Date
AU2007275365A1 true AU2007275365A1 (en)	2008-01-24

Family

ID=38957565

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU2007275365A Abandoned AU2007275365A1 (en)	2006-07-17	2007-07-17	RNA interference mediated inhibition of Proprotein Convertase Subtilisin Kexin 9 (PCSK9) gene expression using short interfering nucleic acid (siNA)

Country Status (6)

Country	Link
EP (1)	EP2052079A2 (fr)
JP (1)	JP2010503382A (fr)
CN (1)	CN102124107A (fr)
AU (1)	AU2007275365A1 (fr)
CA (1)	CA2658183A1 (fr)
WO (1)	WO2008011431A2 (fr)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7935812B2 (en)	2002-02-20	2011-05-03	Merck Sharp & Dohme Corp.	RNA interference mediated inhibition of hepatitis C virus (HCV) expression using short interfering nucleic acid (siNA)
US7404969B2 (en)	2005-02-14	2008-07-29	Sirna Therapeutics, Inc.	Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
WO2007086883A2 (fr)	2005-02-14	2007-08-02	Sirna Therapeutics, Inc.	Compositions à base de nanoparticules lipidiques et méthodes pour l'administration de molécules biologiquement actives
CN103614375A (zh)	2006-05-11	2014-03-05	阿尔尼拉姆医药品有限公司	抑制pcsk9基因表达的组合物和方法
US20100216864A1 (en) *	2006-10-09	2010-08-26	Ellen Marie Straarup	RNA Antagonist Compounds for the Modulation of PCSK9
US8093222B2 (en)	2006-11-27	2012-01-10	Isis Pharmaceuticals, Inc.	Methods for treating hypercholesterolemia
KR20090103894A (ko) *	2006-11-27	2009-10-01	아이시스 파마수티컬즈 인코포레이티드	고콜레스테롤혈증을 치료하는 방법
JP2011511004A (ja) *	2008-01-31	2011-04-07	アルナイラムファーマシューティカルズインコーポレイテッド	ＰＣＳＫ９遺伝子を標的とするｄｓＲＮＡを送達するための最適化された方法
WO2009114475A2 (fr) *	2008-03-09	2009-09-17	Intradigm Corporation	Compositions comprenant de la pcsk9 humaine et un siarn d’apolipoprotéine b, et procédés d’utilisation de celles-ci
WO2009127680A1 (fr) *	2008-04-16	2009-10-22	Santaris Pharma A/S	Composition pharmaceutique comprenant des oligomères anti-pcsk9
CA2635187A1 (fr) *	2008-06-05	2009-12-05	The Royal Institution For The Advancement Of Learning/Mcgill University	Duplex d'oligonucleotides et leurs utilisations
WO2010026537A1 (fr)	2008-09-05	2010-03-11	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Nouvel ensemble multimodulaire utile à une administration intracellulaire
US9051567B2 (en)	2009-06-15	2015-06-09	Tekmira Pharmaceuticals Corporation	Methods for increasing efficacy of lipid formulated siRNA
BRPI1010689A2 (pt) *	2009-06-15	2016-03-15	Alnylam Pharmaceuticals Inc	"dsrna formulado por lipídios direcionados para o gene pcsk9"
WO2011009697A1 (fr)	2009-07-21	2011-01-27	Santaris Pharma A/S	Oligomères anti-sens ciblant pcsk9
US9187746B2 (en)	2009-09-22	2015-11-17	Alnylam Pharmaceuticals, Inc.	Dual targeting siRNA agents
EP2516010A2 (fr) *	2009-12-23	2012-10-31	Novartis AG	Lipides, compositions lipidiques, et procédés d'utilisation associés
EP2694670B1 (fr)	2011-04-08	2017-07-19	Bio-Rad Laboratories, Inc.	Mélanges de réaction pcr à activité non spécifique réduite
WO2013074974A2 (fr) *	2011-11-18	2013-05-23	Alnylam Pharmaceuticals, Inc.	Agents arni modifiés
JP6002382B2 (ja) *	2011-12-07	2016-10-05	株式会社バイオシンクタンク	遺伝子発現阻害剤及び阻害方法
EP2667197B1 (fr) *	2012-05-25	2015-09-16	Zora Biosciences OY	Biomarqueurs à efficacité et spécificité sensibles pour l'inhibition de proprotéine convertase de subtilisine/kexin de type 9 (PCSK9)
RS56783B9 (sr) *	2012-12-05	2021-12-31	Alnylam Pharmaceuticals Inc	Sastavi pcsk9 irnk i postupci njihovih primena
DK3013959T3 (da)	2013-06-27	2020-02-17	Roche Innovation Ct Copenhagen As	Antisense-oligomerer og konjugater målrettet pcsk9
US9023359B1 (en)	2014-07-15	2015-05-05	Kymab Limited	Targeting rare human PCSK9 variants for cholesterol treatment
US9914769B2 (en)	2014-07-15	2018-03-13	Kymab Limited	Precision medicine for cholesterol treatment
US9034332B1 (en)	2014-07-15	2015-05-19	Kymab Limited	Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
US9045548B1 (en)	2014-07-15	2015-06-02	Kymab Limited	Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment
US9051378B1 (en)	2014-07-15	2015-06-09	Kymab Limited	Targeting rare human PCSK9 variants for cholesterol treatment
US8883157B1 (en)	2013-12-17	2014-11-11	Kymab Limited	Targeting rare human PCSK9 variants for cholesterol treatment
FR3014695A1 (fr) *	2013-12-17	2015-06-19	Kymab Ltd
US9139648B1 (en)	2014-07-15	2015-09-22	Kymab Limited	Precision medicine by targeting human NAV1.9 variants for treatment of pain
GB2537614A (en) *	2015-04-20	2016-10-26	Heart Biotech Ltd	Formulations for inhibition of PCSK9 for the treatment of hypercholesterolemia
KR102827366B1 (ko) *	2015-05-06	2025-07-03	알닐람 파마슈티칼스 인코포레이티드	인자 ＸＩＩ(하게만 인자)(Ｆ12), 칼리크레인 Ｂ, 혈장(플레처 인자) 1(ＫＬＫＢ1) 및 키니노겐 1(ＫＮＧ1) ｉＲＮＡ 조성물 및 그의 이용 방법
CA2996701C (fr)	2015-08-25	2024-05-28	Alnylam Pharmaceuticals, Inc.	Procedes et compositions pour le traitement d'un trouble associe a un gene de proproteine convertase subtilisine kexine (pcsk9)
CN116064544A (zh) *	2016-01-26	2023-05-05	日产化学株式会社	单链寡核苷酸
US11655469B2 (en) *	2016-03-07	2023-05-23	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	MicroRNAs and methods of their use
DK3440463T3 (da) *	2016-04-05	2020-10-12	Univ Strasbourg	Manipulation af overflade mellem dråber for indfangning af et molekylært mål
EP3521430A4 (fr) *	2016-09-29	2020-05-20	National University Corporation Tokyo Medical and Dental University	Complexe d'acide nucléique bicaténaire comprenant un surplomb
JP7461886B2 (ja) *	2017-11-13	2024-04-04	サイレンス・セラピューティクス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング	標的遺伝子の発現を抑制するためのジチオリン酸結合を含む核酸
CN110945130B (zh)	2017-12-01	2024-04-09	苏州瑞博生物技术股份有限公司	一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
KR102756073B1 (ko)	2017-12-01	2025-01-20	쑤저우 리보 라이프 사이언스 컴퍼니, 리미티드	이중-가닥 올리고뉴클레오티드, 조성물 및 이중-가닥 올리고뉴클레오티드를 포함하는 접합체, 그의 제조 방법 및 그의 용도
JP7365052B2 (ja)	2017-12-01	2023-10-19	スーチョウリボライフサイエンスカンパニー、リミテッド	核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用
US11414665B2 (en)	2017-12-01	2022-08-16	Suzhou Ribo Life Science Co., Ltd.	Nucleic acid, composition and conjugate comprising the same, and preparation method and use thereof
CN110945132B (zh)	2017-12-01	2024-04-05	苏州瑞博生物技术股份有限公司	一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
US20230139322A1 (en) *	2017-12-26	2023-05-04	Guangzhou Ribobio Co., Ltd.	SiRNA molecule inhibiting the expression of the PCSK9 gene and use thereof
CN109957565B (zh) *	2017-12-26	2023-04-07	广州市锐博生物科技有限公司	一种修饰的siRNA分子及其应用
CN109957567B (zh) *	2017-12-26	2022-09-23	阿格纳生物制药有限公司	一种抑制PCSK9基因表达的siRNA分子及其应用
DK3732185T3 (da)	2017-12-29	2025-03-31	Suzhou Ribo Life Science Co Ltd	Konjugater og fremstilling og anvendelse heraf
CN112368381A (zh) *	2018-04-18	2021-02-12	迪克纳制药公司	用于治疗高胆固醇血症和相关病况的pcsk9靶向寡核苷酸
WO2020038377A1 (fr)	2018-08-21	2020-02-27	苏州瑞博生物技术有限公司	Acide nucléique, composition et conjugué contenant un acide nucléique et leur procédé d'utilisation
EP3862024A4 (fr)	2018-09-30	2022-08-17	Suzhou Ribo Life Science Co., Ltd.	Conjugué d'arn interférent court, son procédé de préparation et utilisation associée
CN109666727B (zh) *	2018-12-29	2020-11-06	中国药科大学	一种高活性抑制pcsk9表达的微小rna的用途
CN113727732B (zh) *	2019-03-20	2023-08-08	雷杰纳荣制药公司	用固醇调节元件结合转录因子1(srebf1)抑制剂治疗脂质水平升高
TWI872073B (zh) *	2019-05-22	2025-02-11	大陸商蘇州瑞博生物技術股份有限公司	siRNA綴合物、其用途及使用其之方法
WO2021037972A1 (fr) *	2019-08-27	2021-03-04	Sanofi	Compositions et procédés d'inhibition de pcsk9
JP2023519140A (ja)	2020-03-16	2023-05-10	アルゴノートアールエヌエーリミテッド	Ｐｃｓｋ９のアンタゴニスト
EP4372086A1 (fr) *	2021-07-16	2024-05-22	Suzhou Ribo Life Science Co., Ltd.	Oligonucléotide double brin, composition et conjugué contenant un oligonucléotide double brin, procédés de préparation et utilisations
CA3229020A1 (fr) *	2021-09-14	2023-03-23	Stella Khan	Traitement d'une maladie cardiovasculaire
WO2024104416A1 (fr) *	2022-11-17	2024-05-23	北京福元医药股份有限公司	Arnsi pour inhiber l'expression du gène scap, son conjugué, sa composition pharmaceutique et son utilisation
WO2024228030A2 (fr) *	2023-05-04	2024-11-07	Argonaute RNA Limited	Silençage double

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20070173473A1 (en) *	2001-05-18	2007-07-26	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of proprotein convertase subtilisin Kexin 9 (PCSK9) gene expression using short interfering nucleic acid (siNA)
US20060148743A1 (en) *	2001-05-18	2006-07-06	Vasant Jadhav	RNA interference mediated inhibition of histone deacetylase (HDAC) gene expression using short interfering nucleic acid (siNA)
AU2004263830B2 (en) *	2003-06-13	2008-12-18	Alnylam Pharmaceuticals, Inc.	Double-stranded ribonucleic acid with increased effectiveness in an organism
US20090130691A1 (en) *	2005-09-16	2009-05-21	Institut De Recherches Cliniques De Montreal	Screening proteinase modulators using a chimeric protein and ski-i proprotein convertase substrates and inhibitors
AU2007258117B2 (en) *	2006-05-05	2013-05-30	Isis Pharmaceuticals, Inc.	Compounds and methods for modulating gene expression

2007
- 2007-07-17 WO PCT/US2007/073723 patent/WO2008011431A2/fr not_active Ceased
- 2007-07-17 JP JP2009520964A patent/JP2010503382A/ja not_active Withdrawn
- 2007-07-17 CA CA002658183A patent/CA2658183A1/fr not_active Abandoned
- 2007-07-17 CN CN2007800269961A patent/CN102124107A/zh active Pending
- 2007-07-17 EP EP07813032A patent/EP2052079A2/fr not_active Withdrawn
- 2007-07-17 AU AU2007275365A patent/AU2007275365A1/en not_active Abandoned

Also Published As

Publication number	Publication date
WO2008011431A3 (fr)	2008-07-17
CA2658183A1 (fr)	2008-01-24
WO2008011431A2 (fr)	2008-01-24
EP2052079A2 (fr)	2009-04-29
CN102124107A (zh)	2011-07-13
JP2010503382A (ja)	2010-02-04
WO2008011431A8 (fr)	2009-11-05

Publication	Publication Date	Title
AU2007275365A1 (en)	2008-01-24	RNA interference mediated inhibition of Proprotein Convertase Subtilisin Kexin 9 (PCSK9) gene expression using short interfering nucleic acid (siNA)
US7935812B2 (en)	2011-05-03	RNA interference mediated inhibition of hepatitis C virus (HCV) expression using short interfering nucleic acid (siNA)
US20070173473A1 (en)	2007-07-26	RNA interference mediated inhibition of proprotein convertase subtilisin Kexin 9 (PCSK9) gene expression using short interfering nucleic acid (siNA)
US20090156533A1 (en)	2009-06-18	RNA INTERFERENCE MEDIATED INHIBITION OF STROMAL CELL-DERIVED FACTOR-1 (SDF-1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US20090239931A1 (en)	2009-09-24	RNA INTERFERENCE MEDIATED INHIBITION OF PROTEIN TYROSINE PHOSPHATASE-1B (PTP-1B) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US20110313024A1 (en)	2011-12-22	RNA INTERFERENCE MEDIATED INHIBITION OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9 (PCSK9) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US7897753B2 (en)	2011-03-01	RNA interference mediated inhibition of XIAP gene expression using short interfering nucleic acid (siNA)
US20050196781A1 (en)	2005-09-08	RNA interference mediated inhibition of STAT3 gene expression using short interfering nucleic acid (siNA)
US7662952B2 (en)	2010-02-16	RNA interference mediated inhibition of GRB2 associated binding protein (GAB2) gene expression using short interfering nucleic acid (siNA)
CA2633684A1 (fr)	2007-07-05	Inhibition a mediation par interference arn de l'expression du gene du virus de l'hepatite c (vhc) au moyen d'acide nucleique interferent court (sina)
WO2006128141A2 (fr)	2006-11-30	Inhibition, mediee par l'interference d'arn, de l'expression genique du facteur 1 derive des cellules stromales (sdf-1), au moyen d'acide nucleique interferant court (sina)
WO2008011467A2 (fr)	2008-01-24	Inhibition à médiation par l'interférence de l'arn de l'expression du gène de la protéine 1 de liaison à l'élément régulateur de stérol (srebp1) à l'aide d'un acide nucléique interférent court (sina)
US8258288B2 (en)	2012-09-04	RNA interference mediated inhibition of respiratory syncytial virus (RSV) expression using short interfering nucleic acid (siNA)
WO2005007855A2 (fr)	2005-01-27	Inhibition induite par interference d'arn de l'expression du gene b7-h1 au moyen d'acide nucleique a interference courte (sina)
WO2010062817A1 (fr)	2010-06-03	Inhibition véhiculée par arn interférence de l’expression du gène de canal sodique épithélial (enac) utilisant un acide nucléique interférant court (ansi)
WO2007147143A2 (fr)	2007-12-21	Inhibition médiée par l'interférence d'arn de l'expression du gène de la 11-bêta-hydroxystéroïde déshydrogénase 1 (11-bêta-hsd-1) en utilisant un acide nucléique interférent court (ansi)
US20070099858A1 (en)	2007-05-03	RNA interference mediated of inhibition of influenza virus gene expression using short interfering nucleic acid (siNA)
US20060287267A1 (en)	2006-12-21	RNA interference mediated inhibition of respiratory syncytial virus (RSV) expression using short interfering nucleic acid (siNA)
WO2005014811A2 (fr)	2005-02-17	Inhibition a mediation par interference arn de l'expression du gene xiap au moyen d'acide nucleique interferent court
US7928220B2 (en)	2011-04-19	RNA interference mediated inhibition of stromal cell-derived factor-1 (SDF-1) gene expression using short interfering nucleic acid (siNA)
WO2009156853A2 (fr)	2009-12-30	Composés, compositions et procédés utiles pour moduler l’expression de l’expression génique et/ou l’activité de l’histone désacétylase (hdac)
US20070179104A1 (en)	2007-08-02	RNA interference mediated inhibition of winged helix nude (WHN) gene expression using short interfering nucleic acid (siNA)
EP1844147A2 (fr)	2007-10-17	Inhibition a mediation d'interference d'arn de l'expression genique du retinoblastome (rbi) au moyen de l'acide nucleique a interference courte (sina)
US20070173467A1 (en)	2007-07-26	Rna interference mediated inhibition of cholesteryl ester transfer protein (cetp) gene expression using short interfering nucleic acid (sina)
WO2007120527A2 (fr)	2007-10-25	INHIBITION PAR INTERFÉRENCE ARN DE L'EXPRESSION DU VIRUS RESPIRATOIRE SYNCYTIAL (RSV) AU MOYEN D'UN ACIDE NUCLÉIQUE INTERFÉRENT COURT (siNA)

Legal Events

Date	Code	Title	Description
2013-02-14	MK4	Application lapsed section 142(2)(d) - no continuation fee paid for the application